See more : BRONCO BILLY Co., LTD. (3091.T) Income Statement Analysis – Financial Results
Complete financial analysis of Spectrum Pharmaceuticals, Inc. (SPPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spectrum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- K.C.P. Sugar and Industries Corporation Limited (KCPSUGIND.BO) Income Statement Analysis – Financial Results
- HCP PLASTENE BULKPACK LIMITED (HPBL.BO) Income Statement Analysis – Financial Results
- Jeevan Scientific Technology Limited (JSTL.BO) Income Statement Analysis – Financial Results
- PT Prima Andalan Mandiri Tbk (MCOL.JK) Income Statement Analysis – Financial Results
- Pearl Polymers Limited (PEARLPOLY.BO) Income Statement Analysis – Financial Results
Spectrum Pharmaceuticals, Inc. (SPPI)
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.11M | 0.00 | 0.00 | 22.62M | 109.33M | 128.37M | 146.44M | 162.56M | 186.83M | 155.85M | 267.71M | 192.96M | 74.11M | 38.03M | 28.73M | 7.67M | 5.67M | 577.00K | 258.00K | 1.00M | 2.37M | 41.11K | 1.00 | 1.00 | 100.00K | 100.00K | 100.00K |
| Cost of Revenue | 1.79M | 0.00 | 0.00 | 12.01M | 26.76M | 47.22M | 35.84M | 27.69M | 27.04M | 28.58M | 46.63M | 33.84M | 17.44M | 8.15M | 1.19M | 0.00 | 97.00K | 397.00K | 123.00K | 0.00 | 0.00 | 0.00 | -1.13M | -519.88K | -500.00K | -200.00K | 0.00 |
| Gross Profit | 8.32M | 0.00 | 0.00 | 10.61M | 82.58M | 81.15M | 110.60M | 134.87M | 159.79M | 127.27M | 221.07M | 159.13M | 56.67M | 29.88M | 27.53M | 7.67M | 5.58M | 180.00K | 135.00K | 1.00M | 2.37M | 41.11K | 1.13M | 519.88K | 600.00K | 300.00K | 100.00K |
| Gross Profit Ratio | 82.28% | 0.00% | 0.00% | 46.91% | 75.53% | 63.22% | 75.52% | 82.97% | 85.53% | 81.66% | 82.58% | 82.46% | 76.47% | 78.57% | 95.85% | 100.00% | 98.29% | 31.20% | 52.33% | 100.00% | 100.00% | 100.00% | 112,813,400.00% | 51,987,600.00% | 600.00% | 300.00% | 100.00% |
| Research & Development | 42.20M | 87.30M | 109.38M | 79.33M | 94.96M | 65.90M | 58.94M | 50.77M | 69.66M | 46.67M | 42.54M | 27.72M | 57.30M | 21.06M | 26.68M | 33.29M | 17.87M | 12.60M | 6.95M | 3.68M | 12.73M | 20.61M | 38.77M | 20.06M | 8.50M | 4.50M | 600.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.82M | 60.41M | 60.36M | 61.37M | 90.70M | 84.27M | 87.35M | 86.51M | 97.41M | 99.32M | 91.97M | 72.55M | 48.55M | 33.61M | 15.16M | 11.58M | 13.60M | 7.50M | 5.98M | 7.62M | 4.10M | 7.58M | 5.11M | 3.47M | 3.10M | 2.30M | 700.00K |
| Other Expenses | -5.33M | -10.89M | -2.94M | -8.89M | 9.58M | 389.00K | 887.00K | -1.25M | -4.37M | -722.00K | -844.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 81.02M | 147.70M | 169.73M | 140.70M | 213.75M | 177.81M | 172.23M | 175.60M | 191.36M | 166.06M | 141.25M | 103.99M | 109.57M | 58.39M | 42.00M | 44.87M | 31.47M | 20.10M | 12.94M | 11.31M | 16.83M | 28.19M | 45.00M | 24.04M | 12.10M | 7.00M | 1.30M |
| Cost & Expenses | 82.81M | 147.70M | 169.73M | 140.70M | 240.51M | 225.03M | 208.07M | 203.29M | 218.40M | 194.64M | 187.88M | 137.83M | 127.01M | 66.53M | 43.20M | 44.87M | 31.57M | 20.50M | 13.06M | 11.31M | 16.83M | 28.19M | 43.87M | 23.52M | 11.60M | 6.80M | 1.30M |
| Interest Income | 968.00K | 163.00K | 1.34M | 5.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.61M | 0.00 | 0.00 | 83.00K | 0.00 | 0.00 | 776.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 998.00K | 0.00 | 0.00 | -5.00M | 340.00K | 6.80M | 9.44M | 9.07M | 8.58M | 2.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00K | 0.00 | 0.00 | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -4.36M | 286.00K | 261.00K | 3.34M | 28.10M | 27.65M | 25.95M | 38.32M | 24.29M | 20.07M | 6.74M | 5.65M | 4.51M | 3.72M | 610.00K | 255.00K | 198.00K | 682.00K | 425.00K | 346.00K | 1.33M | 2.27M | 1.13M | 519.88K | 500.00K | 200.00K | -300.00K |
| EBITDA | -77.06M | -147.70M | -169.73M | -140.70M | -93.50M | -68.62M | -34.80M | -3.66M | -11.65M | -21.58M | 86.57M | 63.69M | -52.40M | -25.45M | -10.33M | -40.08M | -26.28M | -20.52M | -12.38M | -9.81M | -9.92M | -25.68M | -42.74M | -20.78M | -11.20M | -7.20M | -1.50M |
| EBITDA Ratio | -761.91% | 0.00% | 0.00% | -622.14% | -85.52% | -53.46% | -23.76% | -2.25% | -6.23% | -13.85% | 32.34% | 33.01% | -70.70% | -66.93% | -35.94% | -522.41% | -463.18% | -3,556.15% | -4,797.29% | -980.80% | -418.13% | -62,458.85% | -4,273,686,000.00% | -2,077,988,900.00% | -11,200.00% | -7,200.00% | -1,500.00% |
| Operating Income | -72.70M | -147.70M | -169.73M | -144.03M | -131.18M | -96.66M | -61.63M | -40.73M | -31.57M | -38.79M | 79.82M | 55.13M | -52.90M | -28.51M | -19.17M | -37.20M | -25.89M | -19.92M | -12.80M | -10.47M | -17.51M | -28.15M | -43.87M | -23.52M | -11.50M | -6.70M | -1.20M |
| Operating Income Ratio | -718.78% | 0.00% | 0.00% | -636.89% | -119.98% | -75.30% | -42.08% | -25.06% | -16.90% | -24.89% | 29.82% | 28.57% | -71.37% | -74.97% | -66.74% | -484.81% | -456.43% | -3,452.69% | -4,961.24% | -1,046.80% | -738.28% | -68,469.52% | -4,387,369,500.00% | -2,352,312,900.00% | -11,500.00% | -6,700.00% | -1,200.00% |
| Total Other Income/Expenses | -5.36M | -10.73M | -1.60M | 174.20M | 11.17M | -11.37M | -9.20M | -9.65M | -11.96M | 2.15M | -844.00K | -2.91M | 4.01M | 8.74M | 3.70M | 3.14M | 581.00K | 1.28M | 2.00K | 78.00K | -126.50M | -200.69K | -8.70K | -2.22M | 200.00K | 700.00K | 300.00K |
| Income Before Tax | -78.06M | -158.43M | -171.33M | -144.59M | -120.01M | -108.03M | -70.83M | -50.38M | -43.53M | -36.64M | 78.98M | 52.22M | -48.89M | -19.77M | -22.71M | -34.06M | -25.31M | -18.64M | -12.80M | -10.62M | -20.72M | -28.35M | -43.88M | -25.75M | -11.30M | -6.00M | -900.00K |
| Income Before Tax Ratio | -771.78% | 0.00% | 0.00% | -639.37% | -109.77% | -84.15% | -48.36% | -30.99% | -23.30% | -23.51% | 29.50% | 27.06% | -65.96% | -51.99% | -79.04% | -443.90% | -446.18% | -3,231.02% | -4,960.47% | -1,061.90% | -873.80% | -68,957.67% | -4,388,239,700.00% | -2,574,649,400.00% | -11,300.00% | -6,000.00% | -900.00% |
| Income Tax Expense | 46.00K | 4.00K | -60.00K | -9.21M | 1.00K | -16.78M | -2.31M | 406.00K | 2.19M | 25.50M | -15.57M | 3.70M | -43.00K | -421.00K | 997.00K | -3.16M | -2.61M | -1.28M | -514.00K | 85.00K | 3.18M | -315.05K | 2.55M | 2.47M | 100.00K | -500.00K | 100.00K |
| Net Income | -78.10M | -158.44M | -171.27M | -135.39M | -120.01M | -91.25M | -68.51M | -50.79M | -45.72M | -62.13M | 94.55M | 48.52M | -48.84M | -19.05M | -15.47M | -34.04M | -23.28M | -18.64M | -12.29M | -10.39M | -17.63M | -27.83M | -46.43M | -25.99M | -11.60M | -6.20M | -1.00M |
| Net Income Ratio | -772.24% | 0.00% | 0.00% | -598.66% | -109.77% | -71.08% | -46.78% | -31.24% | -24.47% | -39.87% | 35.32% | 25.14% | -65.90% | -50.09% | -53.85% | -443.64% | -410.44% | -3,230.85% | -4,762.02% | -1,039.00% | -743.61% | -67,703.21% | -4,642,728,700.00% | -2,598,990,500.00% | -11,600.00% | -6,200.00% | -1,000.00% |
| EPS | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.61 | 0.94 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| EPS Diluted | -0.43 | -1.02 | -1.38 | -1.22 | -1.16 | -1.07 | -0.94 | -0.78 | -0.71 | -1.02 | 1.46 | 0.86 | -0.99 | -0.48 | -0.49 | -1.17 | -0.96 | -1.06 | -0.97 | -2.49 | -12.34 | -40.42 | -122.82 | -91.45 | -51.64 | -716.85 | -7.41 |
| Weighted Avg Shares Out | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 58.59M | 53.27M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
| Weighted Avg Shares Out (Dil) | 183.24M | 154.86M | 124.39M | 110.59M | 103.31M | 85.12M | 72.82M | 64.88M | 64.71M | 60.73M | 64.64M | 57.96M | 49.50M | 39.27M | 31.55M | 29.01M | 24.31M | 17.66M | 12.67M | 4.17M | 1.43M | 688.62K | 378.02K | 284.20K | 224.62K | 8.65K | 134.98K |
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action- SPPI
NEW YORK , Jan. 3, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - January 3, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b)...
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated by the Firm- SPPI
New York, New York--(Newsfile Corp. - January 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates...
INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - December 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b)...
ROSEN, A LEADING NATIONAL FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
New York, New York--(Newsfile Corp. - December 29, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both...
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - December 29, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b)...
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Spectrum Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - December 28, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ("Spectrum" or "the Company") (NASDAQ: SPPI) for violations of §§10(b)...
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
NEW YORK , Dec. 27, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both dates inclusive (the...
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
BOSTON--( BUSINESS WIRE )--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that on December 27, 2022, Spectrum's Board of Directors granted an aggregate of 206,059 inducement restricted stock units (“RSUs”) to commercial...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPPI
New York, New York--(Newsfile Corp. - December 25, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between December 6, 2021 and September 22, 2022, both...
Source: https://incomestatements.info
Category: Stock Reports